Camena Bioscience appoints Gregory P. McGuinness as CEO

Internationally recognised business executive with extensive operational experience in life sciences, diagnostics and pharma Appointment will lead strategic growth plans, including commercialisation of the gSynth® platform for AI-driven antibody discover

Camena Bioscience close $10 Series A financing as demand for DNA synthesis technology increases

Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, today announced it has closed a $10m Series A financing round, led by Mercia. The new funding will be used to scale operations and continue development of its pioneering DNA synthesis platform, gSynth™.

Camena Bioscience closes $10m Series A financing as demand for DNA synthesis technology increases

Cambridge, UK - Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, announces it has closed a $10m Series A financing round, led by Mercia. The new funding will be used to scale operations and continue development of its pioneering DNA synthesis platform, gSynth™.

Synthetic biology company, Camena Bioscience, expands presence at Chesterford Research Park

Chesterford Research Park is delighted to confirm the expansion of Camena Bioscience within the Science Village Building at the Park.  The developer of an industry-leading DNA synthesis technology has renewed its existing lease for a further five years and in tandem taken an additional 1,993 sq ft adjoining suite on the same terms.